Academy

Catherine Wu, MD - CLL Proteonomics and Immunoproteomics

Nitin Jain, MD - How I Choose Which Frontline Treatment for Who

Danielle M. Brander, MD - Dealing with Autoimmune Complications in CLL

Panel Discussion

Carolyn Owen, MD - MRD in CLL, Ready for Use?

Mazyar Shadman, MD - Richter Syndrome, What’s on the Horizon?

Nicole Lamanna, MD - Alternating Viewpoints: Doublets or Triplets in First-Line CLL - Doublets are Good Enough

John N. Allan, MD - Alternating Viewpoints: Doublets or Triplets in First-Line CLL - Three is Better than Two

Panel Discussion

David Maloney, MD - CAR-T in CLL

Catherine Coombs, MD - Non-covalent BTKi

Alexey Danilov, MD - BTK Degraders

Panel Discussion

Matthew Davids, MD - Debate: Continuous vs Fixed Duration Therapy in Frontline CLL - Fixed Duration

Alessandra Ferrajoli, MD - Debate: Continuous vs Fixed Duration Therapy in Frontline CLL - Continuous Therapy is the Way to Go

Jennifer Brown, MD - CNS Disease in CLL

Richard R. Furman, MD - CLL Next Questions

Panel Discussion

Elise Chong, MD - Innovative Approaches for Relapsed Treatment of DLBCL

Jean Koff, MD - Applying Biological Insights to Aggressive Lymphomas

Jordan S. Goldstein, MD - Applications of cfDNA in DLBCL

Panel Discussion

Christopher Flowers, MD - Applications of Real World Evidence to Inform Lymphoma Clinical Trials

Dai Chihara, MD - Novel Use of RWE to Design Lymphoma Trials

Matthew Maurer, MD - Debate: Improving Lymphoma Clinical Trial Design to Accelerate Drug Approval - Biostatistician’s View

Dai Chihara, MD - Debate: Improving Lymphoma Clinical Trial Design to Accelerate Drug Approval - Clinician’s View

Panel Discussion